- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03123471
A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp (STYLE)
A Phase 3, Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp
This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study of the efficacy and safety of apremilast (CC-10004) in subjects with moderate to severe plaque psoriasis of the scalp.
Approximately 300 subjects with moderate to severe plaque psoriasis of the scalp will be randomized 2:1 to receive either apremilast 30 mg twice daily (BID) or placebo for the first 16 weeks.
Study Overview
Detailed Description
The study will consist of four phases:
- Screening Phase - up to 35 days
Double-blind Placebo-controlled Phase- Weeks 0 to 16 Subjects will receive treatment with one of the following:
- apremilast 30 mg tablets orally BID or
- placebo tablets (identical in appearance to apremilast 30 mg tablets) orally BID
Apremilast Extension Phase - Weeks 16 to 32
- All subjects who had received placebo during the placebo-controlled phase will be switched to apremilast 30 mg BID (or continue with) apremilast. At Week 16, all subjects will maintain this dosing through Week 32.
Observational Follow-up Phase
- Four-week Post-Treatment Observational Follow-up Phase for all subjects who complete the study or discontinue from the study early.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Expanded Access
Contacts and Locations
Study Locations
-
-
-
Quebec, Canada, G1V 4X7
- Centre de Recherche Dermatologique du Quebec Metropolitain CRDQ
-
-
Alberta
-
Calgary, Alberta, Canada, T2G 1B1
- Kirk Barber Research
-
Calgary, Alberta, Canada, T3A 2N1
- Institute for Skin Advancement
-
-
British Columbia
-
Surrey, British Columbia, Canada, V3R 6A7
- Chih-Ho Hong Medical, Inc.
-
Surrey, British Columbia, Canada, V3V 0C6
- Enverus Medical Research
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3M 3Z4
- Wiseman Dermatology Research Inc.
-
-
Ontario
-
Markham, Ontario, Canada, L3P1X2
- Lynderm Research
-
North Bay, Ontario, Canada, P1B 3Z7
- North Bay Dermatology Center
-
Peterborough, Ontario, Canada, K9J 5K2
- Skin Center for Dermatology
-
Richmond Hill, Ontario, Canada, L4B 1A5
- Centre For Dermatology and Cosmetic Surgery
-
Toronto, Ontario, Canada, M3H 5Y8
- The Toronto Dermatology Centre
-
Waterloo, Ontario, Canada, N2J 1C4
- K. Papp Clinical Research
-
Windsor, Ontario, Canada, N8W 1E6
- Xlr8 Medical Research
-
-
-
-
Arkansas
-
Rogers, Arkansas, United States, 72758
- Northwest Arkansas Clinical Trials Center, PLLC / Hull Dermatology
-
-
California
-
Fountain Valley, California, United States, 92708
- Tien Q. Nguyen MD Inc
-
Los Angeles, California, United States, 90045
- Dermatology Research Associates
-
San Luis Obispo, California, United States, 93405
- San Luis Dermatology and Laser Clinic
-
-
Connecticut
-
Farmington, Connecticut, United States, 06030
- University of Connecticut
-
-
Florida
-
Coral Gables, Florida, United States, 33134
- Florida Academic Centers Research and Education
-
Miami, Florida, United States, 33144
- International Dermatology Research
-
Ocala, Florida, United States, 34470
- Renstar Medical Research
-
-
Georgia
-
Macon, Georgia, United States, 31217
- Dermatologic Surgery Specialists, P.C.
-
Newnan, Georgia, United States, 30263
- Medaphase Inc
-
-
Indiana
-
Plainfield, Indiana, United States, 46168
- The Indiana Clinical Trials Center, PC
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- DS Research
-
Louisville, Kentucky, United States, 40241
- DS Research
-
-
Louisiana
-
Lake Charles, Louisiana, United States, 70605
- Dermatology and Advanced Aesthetics
-
-
Maryland
-
Rockville, Maryland, United States, 20850
- Lawrence Green, MD, LLC
-
-
Missouri
-
Saint Louis, Missouri, United States, 63117
- Central Dermatology
-
-
Nebraska
-
Omaha, Nebraska, United States, 68144
- Skin Specialists, PC
-
-
New Jersey
-
East Windsor, New Jersey, United States, 08520
- Psoriasis Treatment Center of Central New Jersey
-
-
New York
-
Brooklyn, New York, United States, 11203
- SUNY Downstate Medical Center
-
Forest Hills, New York, United States, 11375
- Forest Hills Dermatology Group
-
New York, New York, United States, 10029
- Icahn School of Medicine at Mount Sinai Medical Center
-
New York, New York, United States, 10075
- Sadick Research Group
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27104
- Wake Forest University Health Sciences
-
-
Ohio
-
Fairborn, Ohio, United States, 45324
- Wright State Physicians
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- University of Pittsburgh Medical Center
-
-
Texas
-
Austin, Texas, United States, 78705
- Austin Dermatology Associates
-
Dallas, Texas, United States, 75231
- Modern Research Associates PLLC
-
Webster, Texas, United States, 77598
- Center for Clinical Studies
-
-
Utah
-
Salt Lake City, Utah, United States, 84107
- University of Utah
-
-
Virginia
-
Norfolk, Virginia, United States, 23507
- Eastern Virginia Medical School
-
Norfolk, Virginia, United States, 23502
- Virginia Clinical Research Inc
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Medical College of Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Subjects must satisfy the following criteria to be enrolled in the study:
- Males or females, ≥ 18 years of age at the time of signing the informed consent document
- Be willing and able to adhere to the study visit schedule and other protocol requirements.
- Have a diagnosis of moderate to severe plaque psoriasis of the scalp at screening and baseline
- Must be a candidate for phototherapy and/or systemic therapy for either body or scalp psoriasis lesions.
- Have moderate to severe plaque psoriasis at screening and baseline
- Must be in good health (except for psoriasis) as judged by the Investigator, based on medical history, physical examination, 12-lead electrocardiogram (ECG), clinical laboratories, and urinalysis
- Must meet laboratory criteria
- Females of childbearing potential (FCBP)* must have a negative pregnancy test at screening and baseline. While on investigational product (IP) and for at least 28 days after taking the last dose of investigational product, FCBP who engage in activity in which conception is possible - must use one of the approved contraceptive** options described below:
Option 1: Any one of the following highly effective methods: hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal ligation; or partner's vasectomy; OR Option 2: Male or female condom (latex condom or nonlatex condom NOT made out of natural [animal] membrane [for example, polyurethane]; PLUS one additional barrier method: (a) diaphragm with spermicide; (b) cervical cap with spermicide; or (c) contraceptive sponge with spermicide.
*A female of childbearing potential is a sexually mature female who 1) has not undergone a hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the surgical removal of both ovaries) or 2) has not been postmenopausal for at least 24 consecutive months (that is, has had menses at any time during the preceding 24 consecutive months).
** The female subject's chosen form of contraception must be effective by the time the female subject is randomized into the study (for example, hormonal contraception should be initiated at least 28 days before randomization).
Exclusion Criteria:
The presence of any of the following will exclude a subject from enrollment:
- Other than psoriasis, history of any clinically significant uncontrolled disease.
Any condition, including the presence of laboratory abnormalities, which would place the subject at unacceptable risk if he/she were to participate in the study.
- Pregnant or breast feeding
- Hepatitis B surface antigen positive at screening
- Anti-hepatitis C antibody positive at screening
- Active tuberculosis (TB) or a history of incompletely treated TB
- Clinically significant abnormality on 12-lead electrocardiogram (ECG) at screening
- History of positive human immunodeficiency virus (HIV), or have congenital or acquired immunodeficiency (eg, common variable immunodeficiency disease)
- Active substance abuse or a history of substance abuse within 6 months prior to signing the informed consent form.
- Bacterial infections requiring treatment with oral or injectable antibiotics, or significant viral or fungal infections, within 4 weeks of signing the informed consent form.
- Malignancy or history of malignancy, except for treated (i.e., cured) basal cell or squamous cell in situ skin carcinomas or treated (i.e., cured) cervical intraepithelial neoplasia (CIN) or carcinoma in situ of the cervix with no evidence of recurrence within 5 years of signing the informed consent.
- Prior history of suicide attempt at any time in the subject's life time prior to signing the informed consent and randomization, or major psychiatric illness requiring hospitalization within the last 3 years prior to signing the informed consent.
- Psoriasis flare/rebound within 4 weeks of signing the informed consent form or between the screening and baseline visits.
- Topical therapy within 2 weeks prior to randomization; Conventional systemic therapy for psoriasis within 4 weeks prior to randomization; Intralesional corticosteroids on the scalp within 2 weeks prior to randomization; Phototherapy treatment of body or scalp psoriasi lesions within 4 weeks prior to randomization; Biologic therapy between 12 weeks to 24 weeks prior to randomization
- Use of any investigational drug beginning 4 weeks prior to randomization, or 5 pharmacokinetic/pharmacodynamic half-lives, if known (whichever is longer)
- Prolonged sun exposure or use of tanning booths or other ultraviolet (UV) light sources
- Prior treatment with apremilast
- History of allergy or hypersensitivity to any components of the Investigational product.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Apremilast 30 mg BID
Apremilast 30 mg tablets orally twice daily (BID) during Weeks 0 to 32
|
Apremilast 30 mg tablets BID from weeks 0 to 32.
Other Names:
Placebo tablets twice daily (BID) for 16 weeks; placebo participants were switched to apremilast 30 mg at week 16.
|
Placebo Comparator: Placebo
Placebo tablets BID during weeks 0 to 16; at week 16, placebo participants were switched to apremilast 30 mg tablets BID for 16 weeks (from Week 16 to Week 32)
|
Placebo tablets twice daily (BID) for 16 weeks; placebo participants were switched to apremilast 30 mg at week 16.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Scalp Physician Global Assessment (ScPGA) Score of Clear (0) or Almost Clear (1) With at Least a 2-Point Reduction From Baseline
Time Frame: Baseline to Week 16
|
The ScPGA is a measurement of overall scalp involvement by the investigator at the time of evaluation.
The ScPGA is a 5-point scale ranging from 0 (clear) to 4 (severe), incorporating an assessment of the severity of the 3 primary signs of the disease: erythema, scaling, and plaque elevation.
When making the assessment of overall scalp severity, the investigator factored in areas that had already been cleared (ie, had scores of 0), not limited to the evaluation of remaining lesions for severity; consequently, the severity of each sign was averaged across all areas of involvement, including cleared lesions.
|
Baseline to Week 16
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With ≥ 4-Point Reduction (Improvement) From Baseline in the Whole Body Itch Numeric Rating Score at Week 16
Time Frame: Baseline to Week 16
|
The Whole Body Itch NRS scale is an 11-point scale to assess whole body itch.
The scale ranges from 0-10, where "0" represents no itch, and "10" represents the worst imaginable itch, and a 4-point change from baseline was shown to be optimal for demonstrating a level of clinically meaningful improvement in itch severity.
NRS response was defined as a ≥ 4-point reduction (improvement) from baseline.
|
Baseline to Week 16
|
Percentage of Participants With ≥ 4-Point Reduction (Improvement) From Baseline in the Scalp Itch Numeric Rating Score (NRS) at Week 16
Time Frame: Baseline to Week 16
|
The scalp itch NRS is a 11-point scale to assess scalp itch.
The scale ranges from 0-10, where "0" represents no itch, and "10" represents the worst imaginable itch.
|
Baseline to Week 16
|
Percentage of Participants With ≥ 4-Point Reduction (Improvement) From Baseline in the Whole Body Itch NRS Score by Visit in the Placebo-Controlled Phase
Time Frame: Baseline to Weeks 2, 4, 6, 8 and 12
|
The Whole Body Itch NRS scale is a 11-point scale to assess whole body itch.
The scale ranges from 0-10, where "0" represents no itch, and "10" represents the worst imaginable itch, and a 4-point change from baseline was shown to be optimal for demonstrating a level of clinically meaningful improvement in itch severity.
|
Baseline to Weeks 2, 4, 6, 8 and 12
|
Percentage of Participants With ≥ 4-Point Reduction (Improvement) From Baseline in the Scalp Itch NRS Score by Visit in the Placebo-Controlled Phase
Time Frame: Baseline to Weeks 2, 4, 8 and 12
|
The scalp itch NRS is a 11-point scale to assess scalp itch.
The scale ranges from 0-10, where "0" represents no itch, and "10" represents the worst imaginable itch.
|
Baseline to Weeks 2, 4, 8 and 12
|
Change From Baseline in Dermatological Life Quality Index (DLQI) Total Score at Week 16
Time Frame: Baseline to Week 16
|
DLQI is questionnaire for use in a dermatology clinical setting to assess limitations related to the impact of skin disease.
The instrument contains ten items dealing with the participant's skin.
With the exception of Item Number 7, the participant responds on a four-point scale, ranging from "Very Much" (score 3) to "Not at All" or "Not relevant" (score 0).
Item Number 7 is a multi-part item, the first part of which ascertains whether the participant's skin prevented them from working or studying (Yes or No, scores 3 or 0 respectively), and if "No," then the subject is asked how much of a problem the skin has been at work or study over the past week, with response alternatives being "A lot," "A little," or "Not at all" (scores 2, 1, or 0 respectively).
The DLQI total score was derived by summing all item scores, and has a possible range of 0 to 30, with 30 corresponding to the worst quality of life, and 0 corresponding to the best.
|
Baseline to Week 16
|
Number of Participants With Treatment Emergent Adverse Events (TEAE) During the Placebo-Controlled Phase
Time Frame: Week 0 to Week 16; mean duration of exposure was 14.5 weeks and 14.6 weeks for participants randomized to placebo and apremilast respectively.
|
A TEAE is an AE with a start date on or after the date of the first dose of study drug and no later than 28 days after the last dose of study drug.
A serious AE (SAE) is any untoward AE that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly/birth defect, or is a condition that may jeopardize or may require intervention to prevent one of the outcomes above.
The severity of AEs was assessed based on the following scale: Mild = asymptomatic or mild symptoms, clinical or diagnostic observations only; Moderate = symptoms cause moderate discomfort; Severe = could be non-serious or serious) = symptoms causing severe pain discomfort.
|
Week 0 to Week 16; mean duration of exposure was 14.5 weeks and 14.6 weeks for participants randomized to placebo and apremilast respectively.
|
Number of Participants With Treatment Emergent Adverse Events During the Apremilast-Extension Phase
Time Frame: Weeks 16 to Week 32; the mean treatment duration was 14.6 weeks and 15.3 weeks in the APR 30/APR 30 BID and placebo/APR 30 BID arms, respectively
|
A TEAE is an AE with a start date on or after the date of the first dose of study drug and no later than 28 days after the last dose of study drug.
A serious AE (SAE) is any untoward AE that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly/birth defect, or is a condition that may jeopardize or may require intervention to prevent one of the outcomes above.
The severity of AEs was assessed based on the following scale: Mild = asymptomatic or mild symptoms, clinical or diagnostic observations only; Moderate = symptoms cause moderate discomfort; Severe = could be non-serious or serious) = symptoms causing severe pain discomfort.
|
Weeks 16 to Week 32; the mean treatment duration was 14.6 weeks and 15.3 weeks in the APR 30/APR 30 BID and placebo/APR 30 BID arms, respectively
|
Number of Participants With Treatment Emergent Adverse Events During the Apremilast-Exposure Period
Time Frame: Week 0 to 32;
|
The apremilast-exposure period started on the date of the first dose of apremilast (Week 0 for participants originally randomized to apremilast or Week 16 for participants originally randomized to placebo) to the last dose of apremilast.
A TEAE is an AE with a start date on or after the date of the first dose of study drug and no later than 28 days after the last dose of study drug.
A serious AE (SAE) is any untoward AE that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly/birth defect, or is a condition that may jeopardize or may require intervention to prevent one of the outcomes above.
The severity of AEs was assessed based on the following scale: Mild = asymptomatic or mild symptoms, clinical or diagnostic observations only; Moderate = symptoms cause moderate discomfort; Severe = could be non-serious or serious) = symptoms causing severe pain discomfort.
|
Week 0 to 32;
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Skin Diseases, Papulosquamous
- Psoriasis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Phosphodiesterase Inhibitors
- Phosphodiesterase 4 Inhibitors
- Apremilast
Other Study ID Numbers
- CC-10004-SPSO-001
- U1111-1194-1248 (Registry Identifier: WHO)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Informed Consent Form (ICF)
- Clinical Study Report (CSR)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psoriasis
-
ProgenaBiomeRecruitingPsoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Face | Psoriasis Nail | Psoriasis Diffusa | Psoriasis Punctata | Psoriasis Palmaris | Psoriasis Circinata | Psoriasis Annularis | Psoriasis Genital | Psoriasis GeographicaUnited States
-
Clin4allRecruitingPsoriasis of Scalp | Psoriasis Nail | Psoriasis Palmaris | Psoriasis Genital | Psoriasis PlantarisFrance
-
Innovaderm Research Inc.CompletedScalp Psoriasis | Pustular Palmo-plantar Psoriasis | Non-pustular Palmo-plantar Psoriasis | Elbow Psoriasis | Lower Leg PsoriasisCanada
-
Centre of Evidence of the French Society of DermatologyRecruitingPsoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Palmaris | Psoriatic Erythroderma | Psoriatic Nail | Psoriasis Guttate | Psoriasis Inverse | Psoriasis PustularFrance
-
UCB Biopharma S.P.R.L.CompletedModerate to Severe Psoriasis | Generalized Pustular Psoriasis and Erythrodermic PsoriasisJapan
-
AmgenCompletedPsoriasis-Type Psoriasis | Plaque-Type PsoriasisUnited States
-
TakedaRecruitingGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Janssen Pharmaceutical K.K.RecruitingGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Eli Lilly and CompanyCompletedGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Shanghai Huaota Biopharmaceutical Co., Ltd.RecruitingGeneralized Pustular Psoriasis (GPP)China
Clinical Trials on Apremilast
-
AmgenCompletedHealthy VolunteersUnited States
-
AmgenCompletedPsoriasis | Plaque-type PsoriasisUnited States, Canada
-
Diamant ThaciWithdrawnModerate to Severe Plaque PsoriasisGermany
-
University Hospitals Cleveland Medical CenterWithdrawn
-
AmgenCompletedPsoriatic ArthritisUnited States, Italy, Belgium, France, Canada, Taiwan, United Kingdom, Czechia, Russian Federation, Hungary, Germany, Bulgaria, Estonia, South Africa, Poland, Spain
-
AmgenCompletedPsoriatic ArthritisSpain, Canada, United States, Australia, Hungary, Poland, Austria, France, New Zealand, South Africa, Russian Federation, Germany, United Kingdom
-
Postgraduate Institute of Medical Education and...CompletedErythema Nodosum LeprosumIndia
-
Aga Khan UniversityWorld Health OrganizationCompletedPoliomyelitisPakistan
-
Jinnah Postgraduate Medical CentreCompleted
-
AmgenCompleted